ITMI20010562A1 - Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari - Google Patents

Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari

Info

Publication number
ITMI20010562A1
ITMI20010562A1 IT2001MI000562A ITMI20010562A ITMI20010562A1 IT MI20010562 A1 ITMI20010562 A1 IT MI20010562A1 IT 2001MI000562 A IT2001MI000562 A IT 2001MI000562A IT MI20010562 A ITMI20010562 A IT MI20010562A IT MI20010562 A1 ITMI20010562 A1 IT MI20010562A1
Authority
IT
Italy
Prior art keywords
treatment
antagonists
vascular disorders
protein inhibitors
hmg1 protein
Prior art date
Application number
IT2001MI000562A
Other languages
English (en)
Italian (it)
Inventor
Marco E Bianchi
Tiziana Bonaldi
Paola Scaffidi
Susanne Mueller
Bernard Degryse
Original Assignee
Marco E Bianchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marco E Bianchi filed Critical Marco E Bianchi
Priority to US10/471,641 priority Critical patent/US7754217B2/en
Priority to IT2001MI000562A priority patent/ITMI20010562A1/it
Priority to JP2002573044A priority patent/JP4822654B2/ja
Priority to ES02717057T priority patent/ES2346408T3/es
Priority to AU2002247977A priority patent/AU2002247977C1/en
Priority to HK05101837.0A priority patent/HK1069316B/xx
Priority to DK02717057.0T priority patent/DK1368060T3/da
Priority to CA2439530A priority patent/CA2439530C/en
Priority to DE60236413T priority patent/DE60236413D1/de
Priority to MXPA03008364A priority patent/MXPA03008364A/es
Priority to CN200910252323A priority patent/CN101773669A/zh
Priority to PT02717057T priority patent/PT1368060E/pt
Priority to PCT/IT2002/000153 priority patent/WO2002074337A1/en
Priority to AT02717057T priority patent/ATE468137T1/de
Priority to EP02717057A priority patent/EP1368060B1/en
Priority to CN028065670A priority patent/CN1537014B/zh
Publication of ITMI20010562A1 publication Critical patent/ITMI20010562A1/it
Priority to US11/968,506 priority patent/US8058239B2/en
Priority to US12/707,222 priority patent/US20100172896A1/en
Priority to US12/707,264 priority patent/US20100297107A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT2001MI000562A 2001-03-16 2001-03-16 Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari ITMI20010562A1 (it)

Priority Applications (19)

Application Number Priority Date Filing Date Title
US10/471,641 US7754217B2 (en) 2001-03-16 2001-03-16 HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
IT2001MI000562A ITMI20010562A1 (it) 2001-03-16 2001-03-16 Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
MXPA03008364A MXPA03008364A (es) 2001-03-16 2002-03-12 Inhibidores y/o antagonistas de la proteina hmgb1 para el tratamiento de enfermedades vasculares.
PT02717057T PT1368060E (pt) 2001-03-16 2002-03-12 Inibidores e/ou antagonistas da proteína hmgb1 para o tratamento de doenças vasculares
AU2002247977A AU2002247977C1 (en) 2001-03-16 2002-03-12 HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
HK05101837.0A HK1069316B (en) 2001-03-16 2002-03-12 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
DK02717057.0T DK1368060T3 (da) 2001-03-16 2002-03-12 HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
CA2439530A CA2439530C (en) 2001-03-16 2002-03-12 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
DE60236413T DE60236413D1 (de) 2001-03-16 2002-03-12 Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
JP2002573044A JP4822654B2 (ja) 2001-03-16 2002-03-12 血管疾患治療用ｈｍｇｂ１蛋白質インヒビタおよび／またはアンタゴニスト
CN200910252323A CN101773669A (zh) 2001-03-16 2002-03-12 用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂
ES02717057T ES2346408T3 (es) 2001-03-16 2002-03-12 Inhibidores y/o antagonista de la proteina hmgb1 destinados al tratamiento de enfermedades vasculares.
PCT/IT2002/000153 WO2002074337A1 (en) 2001-03-16 2002-03-12 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
AT02717057T ATE468137T1 (de) 2001-03-16 2002-03-12 Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
EP02717057A EP1368060B1 (en) 2001-03-16 2002-03-12 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
CN028065670A CN1537014B (zh) 2001-03-16 2002-03-12 用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂
US11/968,506 US8058239B2 (en) 2001-03-16 2008-01-02 HMGB1 protein inhibitorsand/or antagonists for the treatment of vascular diseases
US12/707,222 US20100172896A1 (en) 2001-03-16 2010-02-17 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
US12/707,264 US20100297107A1 (en) 2001-03-16 2010-02-17 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI000562A ITMI20010562A1 (it) 2001-03-16 2001-03-16 Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari

Publications (1)

Publication Number Publication Date
ITMI20010562A1 true ITMI20010562A1 (it) 2002-09-16

Family

ID=11447291

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2001MI000562A ITMI20010562A1 (it) 2001-03-16 2001-03-16 Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari

Country Status (14)

Country Link
US (4) US7754217B2 (https=)
EP (1) EP1368060B1 (https=)
JP (1) JP4822654B2 (https=)
CN (2) CN1537014B (https=)
AT (1) ATE468137T1 (https=)
AU (1) AU2002247977C1 (https=)
CA (1) CA2439530C (https=)
DE (1) DE60236413D1 (https=)
DK (1) DK1368060T3 (https=)
ES (1) ES2346408T3 (https=)
IT (1) ITMI20010562A1 (https=)
MX (1) MXPA03008364A (https=)
PT (1) PT1368060E (https=)
WO (1) WO2002074337A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
CN100447154C (zh) * 2001-05-15 2008-12-31 费因斯坦医学研究学院 利用hmg片段作为抗炎症试剂
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
AU2003228099A1 (en) 2002-07-03 2004-01-23 Centro Cardiologico Monzino S.P.A.-Irccs Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
WO2004061456A2 (de) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
ITRM20040058A1 (it) * 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
EP1768677B1 (en) * 2004-07-02 2008-06-25 Creabilis Therapeutics S.P.A. Nucleic acids for the treatment of hmgb1-related pathologies
JP2008507505A (ja) 2004-07-20 2008-03-13 プロヴィンシア・イタリアーナ・デッラ・コングレガチォーネ・フィリ・デッリマコラータ・コンセチォーネ−イスティトゥト・デルモパティコ・デッリマコラータ−アイ・アール・シー・シー・エス 創傷治癒のためのｈｍｇｂ１の使用
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
JP5622351B2 (ja) 2004-09-03 2014-11-12 クレアビリス・セラピューティクス・エスピーエー プロテアーゼ抵抗性ヒトおよび非ヒトＨＭＧＢ１Ｂｏｘ−Ａ変異体、ならびにそれらの治療／診断への使用
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
WO2007001422A2 (en) 2004-10-22 2007-01-04 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
ITRM20050032A1 (it) * 2005-01-21 2006-07-22 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica.
WO2006114805A2 (en) * 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
WO2007011606A2 (en) 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
WO2007022999A1 (en) 2005-08-25 2007-03-01 Creabilis Therapeutics S.P.A. Polymer conjugates of k-252a and derivatives thereof
WO2007031100A1 (en) * 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
US7829097B2 (en) * 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
CA2663300C (en) 2006-09-15 2014-10-07 Creabilis Therapeutics S.P.A. Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
JP5225109B2 (ja) 2007-02-15 2013-07-03 国立大学法人 熊本大学 ヒトｈｍｇｂ−１に特異的に結合する抗体を有効成分として含有する治療剤
US8673580B2 (en) 2008-04-30 2014-03-18 Genomix Co., Ltd. Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
JP5676253B2 (ja) 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
EP2455469A4 (en) 2009-07-16 2013-03-13 Nec Software Ltd FOR BINDING TO HMGB1 ABLE NUCLEIC ACID MOLECULE AND USE THEREOF
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
JP5865703B2 (ja) 2009-10-28 2016-02-17 株式会社ジェノミックス 骨髄間葉系および／または多能性幹細胞の血中動員による組織再生促進剤
RU2013123796A (ru) * 2010-10-30 2014-12-10 Исис Инновэйшн Лтд Способ лечения болезни дюпюитрена
PT3358011T (pt) 2011-04-26 2020-04-23 Univ Osaka Péptido para induzir a regeneração de um tecido e a sua utilização
US9244074B2 (en) * 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9688733B2 (en) 2012-10-25 2017-06-27 Genomix Co., Ltd. Method for treating spinal cord injury using HMGB1 fragment
ES2660420T3 (es) 2012-10-25 2018-03-22 Genomix Co., Ltd. Método novedoso para tratar infarto cardiaco utilizando fragmento de HMGB1
CA2897914A1 (en) 2013-01-28 2014-07-31 Evec Inc. Humanized anti-hmgb1 antibody or antigen-binding fragment thereof
IL242807A0 (en) 2015-11-26 2016-04-21 Novamed Ltd Test facility
CN108367049A (zh) 2015-12-11 2018-08-03 海德堡吕布莱希特-卡尔斯大学 Pkm2调节剂和hmgb1的组合制剂
EP3556378B1 (en) 2017-01-27 2025-03-12 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
CN111542335A (zh) 2017-12-01 2020-08-14 斯特姆里姆有限公司 炎症性肠病的治疗药
CN111868231B (zh) 2017-12-01 2024-05-31 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
US20250019405A1 (en) * 2020-04-22 2025-01-16 Chulalongkorn University A Composition and A Method of Rejuvenating DNA and Preventing DNA Damage

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5470307A (en) * 1994-03-16 1995-11-28 Lindall; Arnold W. Catheter system for controllably releasing a therapeutic agent at a remote tissue site
AU1832797A (en) 1996-01-26 1997-08-20 Trustees Of Columbia University In The City Of New York, The A polypeptide from lung extract which binds amyloid-beta peptide
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6398808B1 (en) 1999-06-15 2002-06-04 Scimed Life Systems, Inc. Localized delivery of genetic information from biostable materials
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
CN100447154C (zh) * 2001-05-15 2008-12-31 费因斯坦医学研究学院 利用hmg片段作为抗炎症试剂
ITRM20040058A1 (it) * 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
JP2008507505A (ja) * 2004-07-20 2008-03-13 プロヴィンシア・イタリアーナ・デッラ・コングレガチォーネ・フィリ・デッリマコラータ・コンセチォーネ−イスティトゥト・デルモパティコ・デッリマコラータ−アイ・アール・シー・シー・エス 創傷治癒のためのｈｍｇｂ１の使用
WO2008137552A2 (en) * 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof

Also Published As

Publication number Publication date
US20100297107A1 (en) 2010-11-25
US20080171052A1 (en) 2008-07-17
DE60236413D1 (de) 2010-07-01
AU2002247977B8 (en) 2007-03-15
EP1368060A1 (en) 2003-12-10
AU2002247977A1 (en) 2002-10-03
EP1368060B1 (en) 2010-05-19
DK1368060T3 (da) 2010-08-30
CA2439530C (en) 2016-11-08
US7754217B2 (en) 2010-07-13
HK1069316A1 (en) 2005-05-20
AU2002247977C1 (en) 2008-09-18
AU2002247977B2 (en) 2006-12-14
CN1537014B (zh) 2012-04-25
WO2002074337A8 (en) 2003-08-28
JP2004523579A (ja) 2004-08-05
US8058239B2 (en) 2011-11-15
CA2439530A1 (en) 2002-09-26
AU2002247977A2 (en) 2004-02-26
CN101773669A (zh) 2010-07-14
ATE468137T1 (de) 2010-06-15
US20100172896A1 (en) 2010-07-08
CN1537014A (zh) 2004-10-13
JP4822654B2 (ja) 2011-11-24
ES2346408T3 (es) 2010-10-15
MXPA03008364A (es) 2004-11-12
US20040136979A1 (en) 2004-07-15
WO2002074337A1 (en) 2002-09-26
PT1368060E (pt) 2010-08-24

Similar Documents

Publication Publication Date Title
ITMI20010562A1 (it) Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
IS7215A (is) Aðferðir til að meðhöndla nýæðarsjúkdóma í augum
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
MY162068A (en) Formulation of human antibodies for treating tnf-(alpha) associated disorders
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
DK1296671T3 (da) Gabapentinanaloger til sövnforstyrrelser
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
SE0302304D0 (sv) Novel compounds
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
EA200400399A1 (ru) Способы лечения легочных заболеваний
MY139368A (en) Novel cyclohexyl sulphones
TR200200278T2 (tr) Kalsilitik bileşimler
NO20005548D0 (no) Mykobakterieinhibitorer
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
SE0004827D0 (sv) Therapeutic compounds
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях